Lipella Pharmaceuticals Inc. (LIPO)
Oxford Ledge is still expanding full research coverage of LIPO. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Lipella reformulates generic drugs into new therapeutic candidates for serious diseases with no current approved treatments.
Source: 10-K (2024-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K 1.03 2026-03-31
- 8-K Departure/election of directors or officers 2026-02-04
- 10-Q Quarterly financial report (unaudited) 2025-11-14
- 8-K Departure/election of directors or officers 2025-10-21
- 8-K Departure/election of directors or officers 2025-10-09
Source: SEC EDGAR.
Annual results
4 years of annual figures for LIPO, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2024 | $536,357 | -$5.0M | -$4.79 |
| 2023 | $449,617 | -$4.6M | -$6.16 |
| 2022 | $184,156 | -$2.6M | -$0.64 |
| 2021 | $259,347 | -$1.9M | -$0.55 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for LIPO. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open LIPO in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.